August 27, 2020

Towards Personalized Vasopressor Support

In this episode of Critical Matters, we will discuss hypotension and new data on Angiotensin II within the context of our path towards personalized vasopressor support.

Our guest is Dr. Ashish K. Khanna. Dr. Khanna is an anesthesia and critical care practicing physician. He is Associate Professor, and Section Head for Research, in the Department of Anesthesiology, Section on Critical Care Medicine of the Wake Forest School of Medicine, in Winston-Salem, North Carolina. He is a prolific author and researcher and was the lead author of the ATHOS-3 study in the New England Journal of Medicine. The results of which led to the approval of Angiotensin II as a vasopressor for the treatment of refractory hypotension in adults with septic or other types of distributive shock.

The Relationship Between ICU Hypotension and In-Hospital Mortality and Morbidity in Septic Patients:
Association between Mean Arterial Pressure and Acute Kidney Injury and a Composite of Myocardial Injury and Mortality in Postoperative Critically Ill Patients: A Retrospective Cohort Analysis:
Angiotensin II for the Treatment of Vasodilatory Shock (ATHOS-3 Trial):
Survival After Shock Requiring High-Dose Vasopressor Therapy:
Renin as a Marker of Tissue-Perfusion and Prognosis in Critically Ill Patients:
Renin and Survival in Patients Given Angiotensin II for Catecholamine-Resistant Vasodilatory Shock:

Additional Content Related to Angiotensin II:
Angiotensin II for Vasodilatory Shock: 2019 Update:
Personalization of Vasopressor Therapy in the Treatment of Vasodilatory Shock: